Navigation Links
Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Syncria (Type 2 Diabetes) – Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Syncria (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Syncria (Type 2 Diabetes) – Analysis and Forecasts to 2020" provides Syncria sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 2 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)

- Analysis and review of Syncria

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Syncria including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecast for 2014-2020 for Syncria in the US, EU5 and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 5

2.1 Diabetes 5

2.2 Epidemiology 5

2.2.1 Prevalence 5

2.2.2 Mortality 7

2.3 Etiology and Risk Factors 9

2.3.1 Obesity 9

2.3.2 Sedentary Lifestyle 9

2.3.3 Family History and Genetics 9

2.3.4 Ethnicity 9

2.3.5 Old Age 9

2.4 Economic Impact of Diabetes 9

2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

3.1 Type 2 Diabetes Market 12

3.2 Type 2 Diabetes Market Forecasts 13

3.3 Type 2 Diabetes Market: Drivers and Restraints 14

3.3.1 Drivers 14

3.3.2 Restraints 15

4 Classification of Diabetes 16

4.1 Types of Diabetes 16

4.1.1 Type 1 Diabetes 16

4.1.2 Type 2 Diabetes 16

4.1.3 Gestational Diabetes 16

4.2 Diabetes Complications 16

4.2.1 Cardiovascular Disease 16

4.2.2 Nephropathy 17

4.2.3 Neuropathy 17

4.2.4 Amputation 17

4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19

6.2 Oral Medications 19

6.2.1 Sulfonylureas (SUR) 19

6.2.2 Biguanides (BGDs) 19

6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21

6.2.4 Meglitinides 21

6.2.5 Thiazolidinediones (TZDs) 22

6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23

6.2.7 Oral Combination Therapy 23

6.3 Other Injectionable Medications 24

6.3.1 Pramlintide 24

6.3.2 Exenatide 24

6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Syncria 25

7.1 Introduction 25

7.2 Mechanism of Action 25

7.3 Clinical Studies 25

7.4 Factors Affecting Sales of Syncria 26

7.4.1 Once Weekly Dosage 26

7.4.2 Competition from Januvia 26

7.4.3 Approval of Bydureon 26

7.5 Drug Evaluation 27

7.5.1 Drug Risk Benefit Score 27

7.5.2 Intensity of Competition 27

7.6 Sales Forecasts 28

7.6.1 Target Patient Pool for Syncria 28

7.6.2 Dosing 28

7.6.3 Market Penetration 28

7.6.4 Annual Cost of Syncria 28

7.6.5 Sales Projections of Syncria 29

8 Diabetes Market: Appendix 38

8.1 Market Definitions 38

8.2 List of Abbreviations 38

8.3 Research Methodology 38

8.3.1 Coverage 39

8.3.2 Secondary Research 39

8.3.3 Forecasting 39

8.3.4 Net Penetration of Drug 40

8.3.5 Net Annual Dosing 40

8.3.6 Annual Cost of Therapy 40

8.3.7 Primary Research 40

8.3.8 Expert Panels 40

8.4 Drug Sales Estimates Model 41

8.5 Contact Us 41

8.6 Disclaimer 41

8.7 Sources 41

1.1 List of Tables

Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5

Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7

Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10

Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 11

Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12

Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13

Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14

Table 8: Diabetes Drugs Evolution 17

Table 9: Syncria Phase II Results 24

Table 10: Drug Risk Benefit Score of Syncria 26

Table 11: Estimated Annual Cost of Therapy of Syncria, 2014 27

Table 12: Syncria, Type 2 Diabetes, Global, Sales Forecasts ($m), 2014–2020 28

Table 13: Syncria, Type 2 Diabetes, The US, Sales Forecasts ($m), 2014–2020 29

Table 14: Syncria, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2014–2020 30

Table 15: Syncria, Type 2 Diabetes, France, Sales Forecasts ($m), 2014–2020 31

Table 16: Syncria, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2014–2020 32

Table 17: Syncria, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2014–2020 33

Table 18: Syncria, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2014–2020 34

Table 19: Syncria, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016–2020 35

1.2 List of Figures

Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6

Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6

Figure 3: Diabetes, World, Mortality, 2010 7

Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8

Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 12

Figure 6: Mechanism of Action of Sulfonylurea 18

Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 19

Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 20

Figure 9: Mechanism of Action of Thiazolidinediones 21

Figure 10: Mechanism of Action of DPP IV Inhibitors 22

Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 23

Figure 12: Syncria, Type 2 Diabetes, Global, Sales Forecasts ($m), 2014–2020 28

Figure 13: Syncria, Type 2 Diabetes, The US, Sales Forecasts ($m), 2014–2020 29

Figure 14: Syncria, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2014–2020 30

Figure 15: Syncria, Type 2 Diabetes, France, Sales Forecasts ($m), 2014–2020 31

Figure 16: Syncria, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2014–2020 32

Figure 17: Syncria, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2014–2020 33

Figure 18: Syncria, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2014–2020 34

Figure 19: Syncria, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016–2020 35

Figure 20: Syncria, Type 2 Diabetes, Global, Sales Distribution (%), 2020 36

To order this report:

Pathology Industry: Syncria (Type 2 Diabetes) – Analysis and Forecasts to 2020

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
6. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
9. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
10. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
11. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide ... we as a society can control and change. , As nearly 795,000 Americans suffering ... seconds within the United States. Plus, with an estimated 129,000 of these people dying ...
Breaking Medicine News(10 mins):